Schraa, Suzanna J.
Stelloo, Ellen
Laclé, Miangela M.
Swennenhuis, Joost F.
Brosens, Lodewijk A. A.
Fijneman, Remond J. A.
Feitsma, Harma
Koopman, Miriam
de Leng, Wendy W.
Vink, Geraldine R.
Bol, Guus M. http://orcid.org/0000-0002-4021-3823
Funding for this research was provided by:
Bayer
Article History
Received: 14 February 2023
Revised: 15 March 2023
Accepted: 27 March 2023
First Online: 17 April 2023
Declarations
:
: S.J. Schraa reported grants from Personal Genome Diagnostics (PGDx) outside the submitted work. E. Stelloo, J.F. Swennenhuis, and H. Feitsma are employees of Cergentis BV, the company that invented and owns the FFPE-TLC technology. R.J.A.F. reported public private partnership consortia grants in collaboration with Cergentis BV, Personal Genome Diagnostics, Delfi Diagnostics, MERCK BV, outside the submitted work. In addition, R.J.A.F. has several patents pending. M. Koopman reported institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, Personal Genome Diagnostics (PGDx), Pierre Fabre, Roche, Sirtex and Servier, has an advisory role for Nordic Farma, Merck-Serono, Pierre Fabre, and Servier outside the submitted work and is principal investigator from the international cohort study PROMETCO with Servier as sponsor. W.W. de Leng reported grants from Roche, BMS, and Pfizer and was involved in advisory boards for BMS, Janssen, and Novartis outside the submitted work. G.R. Vink reported grants from BMS, Merck, Servier, Personal Genome Diagnostics (PGDx), Bayer, Sirtex, Pierre Fabre, Lilly, and Delfi Diagnostics outside the submitted work. G.M. Bol reports institutional scientific grants from Bayer, Pierre Fabre, and Terumo. No other disclosures were reported.